# Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

> **NCT02364076** · PHASE2 · UNKNOWN · sponsor: **Georgetown University** · enrollment: 45 (actual)

## Conditions studied

- Thymic Carcinoma
- Thymus Neoplasms
- Thymus Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Epacadostat

## Key facts

- **NCT ID:** NCT02364076
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2019-06
- **Final completion:** 2021-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364076, "Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02364076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*